Patents Examined by Ilia I Ouspenski
  • Patent number: 10253097
    Abstract: An antibody capable of potentiating immune responses and modifying existing states of immune responsiveness is described, as is the sequence of the antibody. Also described are compositions containing the antibody, as well as methods for using the antibody and the compositions to enhance immune responses, to enhance DC function, to modify an existing state of immune responsiveness, to immunize individuals, or to treat or inhibit conditions such as allergic asthma.
    Type: Grant
    Filed: January 6, 2016
    Date of Patent: April 9, 2019
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Larry R. Pease, Virginia Van Keulen, Bogolub Ciric
  • Patent number: 10239942
    Abstract: Antibodies that bind to programmed cell death protein 1 (PD-1), compositions comprising such antibodies, and methods of making and using such antibodies are disclosed.
    Type: Grant
    Filed: December 19, 2015
    Date of Patent: March 26, 2019
    Assignee: PD-1 Acquisition Group, LLC
    Inventors: Najmia Amirina, Hareesh Chamarthi, Maria Isabel Chiu, Daniel Doty, Bin Feng, Aleksander Jonca, Thomas McQuade, Anhco Nguyen, Sheila Ranganath, Hans Albert Felix Scheuplein, Vikki A. Spaulding, Lei Wang, Jennifer Watkins-Yoon, Sri Sahitya Vadde
  • Patent number: 10233242
    Abstract: A method of treating, preventing, or delaying the progression of Type 1 diabetes mellitus autoimmunity by administering an effective amount of a cytotoxic T-lymphocyte-associated antigen 4 (CTLA4) molecule is provided herewith. The CTLA4 molecule may be a fusion protein of a CTLA4 extracellular region and an immunoglobulin, such as abatacept.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: March 19, 2019
    Assignee: DMNOMORE
    Inventor: Tihamer Orban
  • Patent number: 10214586
    Abstract: The present invention relates to antibodies that bind human programmed cell death 1 ligand 1 (PD-L1), and may be useful for treating solid and hematological tumors alone and in combination with chemotherapy and other cancer therapeutics.
    Type: Grant
    Filed: August 18, 2016
    Date of Patent: February 26, 2019
    Assignee: Eli Lilly and Company
    Inventors: Dale Lincoln Ludwig, Marshall Davenport Snavely, Yiwen Li, Juqun Shen, Vera Molkenthin
  • Patent number: 10214585
    Abstract: A pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS that does not include the autoimmune neuroinflammatory disease, relapsing-remitting multiple sclerosis (RRMS), is provided. The pharmaceutical composition is for administration by a dosage regimen comprising at least two courses of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session of non-treatment.
    Type: Grant
    Filed: September 10, 2015
    Date of Patent: February 26, 2019
    Assignee: Yeda Research and Development Co., Ltd.
    Inventors: Michal Eisenbach-Schwartz, Kuti Baruch, Neta Rosenzweig
  • Patent number: 10208119
    Abstract: Provided are anti-PD-L1 antibodies or fragments thereof. The antibodies or fragments thereof specifically bind to the immunoglobulin C domain of the PD-L1 protein. In various example, the antibodies or fragments thereof include a VH CDR1 of SEQ ID NO: 1, a VH CDR2 of SEQ ID NO: 2, a VH CDR3 of SEQ ID NO: 3, a VL CDR1 of SEQ ID NO: 4, a VL CDR2 of SEQ ID NO: 5, and a VL CDR3 of SEQ ID NO: 6, or variants of each thereof. Methods of using the antibodies or fragments thereof for treating and diagnosing diseases such as cancer and infectious diseases are also provided.
    Type: Grant
    Filed: August 9, 2018
    Date of Patent: February 19, 2019
    Assignee: I-MAB
    Inventors: Lei Fang, Zhengyi Wang, Bingshi Guo, Jingwu Zang
  • Patent number: 10208115
    Abstract: The present invention relates to amino acid sequences that block the interaction between (a target on) an antigen presenting cell (APC) and (a target on) a T-cell. More particularly, the present invention relates to amino acid sequences that are directed against (as defined herein) a target on an APC (also referred to herein as “APC target”) or a target on a T-cell (also referred to herein as “T-cell target”). The invention further relates to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences.
    Type: Grant
    Filed: February 23, 2016
    Date of Patent: February 19, 2019
    Assignee: Ablynx N.V.
    Inventors: Guy Hermans, Peter Verheesen, Edward Dolk, Hendricus Renerus Jacobus Mattheus Hoogenboom, Michael John Scott Saunders, Hans De Haard, Renee de Bruin
  • Patent number: 10202453
    Abstract: There is disclosed compositions and methods relating to or derived from anti-CTLA4 antibodies. More specifically, there is disclosed fully human antibodies that bind CTLA4, CTLA4-antibody binding fragments and derivatives of such antibodies, and CTLA4-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating a disease requiring either stimulation of immune responses or suppression.
    Type: Grant
    Filed: February 12, 2016
    Date of Patent: February 12, 2019
    Assignee: Sorrento Therapeutics, Inc.
    Inventors: John Dixon Gray, Heyue Zhou
  • Patent number: 10196445
    Abstract: The present invention provides anti-CTLA-4 antibodies having enhanced ADCC activity, and their use in treating cancer. In one embodiment, the anti-CTLA-4 antibody is ipilimumab, and ADCC activity is enhanced by introducing G236A, S239D, A330L and I332E mutations (“GASDALIE”) into the Fc region of the heavy chain constant domain.
    Type: Grant
    Filed: March 16, 2016
    Date of Patent: February 5, 2019
    Assignee: Bristol-Myers Squibb Company
    Inventors: John J. Engelhardt, Alan J. Korman, Mark J. Selby
  • Patent number: 10196452
    Abstract: The present disclosure provides isolated binding molecules that bind to the human OX40R, nucleic acid molecules encoding an amino acid sequence of the binding molecules, vectors comprising the nucleic acid molecules, host cells containing the vectors, methods of making the binding molecules, pharmaceutical compositions containing the binding molecules, and methods of using the binding molecules or compositions.
    Type: Grant
    Filed: November 8, 2017
    Date of Patent: February 5, 2019
    Assignees: Pfizer Inc., Bristol-Myers Squibb Company
    Inventors: Jing Min, Yanli Wu, Rory F. Finn, Barrett R. Thiele, Wei Liao, Ronald P. Gladue, Arvind Rajpal, Timothy J. Paradis, Peter Brams, Brigitte Devaux, Yi Wu, Kristopher Toy, Heidi N. Leblanc, Haichun Huang
  • Patent number: 10196450
    Abstract: Human antibodies, preferably recombinant human antibodies, both humanized and chimeric, which specifically bind to human OX40 are disclosed. Preferred antibodies have high affinity for OX40 receptor and activate the receptor in vitro and in vivo. The antibody can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, are useful for modulating receptor activity, e.g., in a human subject suffering from a disorder in which OX40 activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies are provided, and methods of synthesizing the recombinant human antibodies, are also provided.
    Type: Grant
    Filed: May 26, 2017
    Date of Patent: February 5, 2019
    Assignee: Board of Regents, The University of Texas System
    Inventors: Yong-Jun Liu, Kui Shin Voo, Laura Bover, Naoya Tsurushita, J. Yun Tso, Shankar Kumar
  • Patent number: 10174113
    Abstract: The invention provides a method of treating a melanoma comprising (i) identifying a patient having a PD-L1-negative melanoma and (ii) administering to the patient a combination of an anti-PD-1 antibody or an antigen-binding portion thereof and an anti-CTLA-4 antibody or an antigen-binding portion thereof. The methods of the invention can extend progression-free survival for over 8 months and/or reduces the tumor size at least about 10%, about 20%, about 30%, about 40%, or about 50% compared to the tumor size prior to the administration.
    Type: Grant
    Filed: April 28, 2016
    Date of Patent: January 8, 2019
    Assignee: Bristol-Myers Squibb Company
    Inventor: Arvin Yang
  • Patent number: 10167337
    Abstract: Agonists to ICOS in combination with a blocking agent to a T cell inhibitory receptor (e.g., CTLA-4, PD-1, etc.) are demonstrated herein to be useful for the treatment of tumors.
    Type: Grant
    Filed: May 4, 2018
    Date of Patent: January 1, 2019
    Assignees: MEMORIAL SLOAN-KETTERING CANCER CENTER, BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: James Allison, Padmanee Sharma, Sergio A. Quezada, Tihui Fu
  • Patent number: 10167336
    Abstract: This document provides methods and materials involved in treating cancer. For example, methods and materials for identifying a mammal as having an elevated level of PD-1+/CD11ahigh CD8 T cells having the potential to exert anti-cancer effects are provided. In addition, methods and materials for identifying a mammal as having an elevated level of PD-1+/CD11ahigh CD8 T cells and administering a PD-1 inhibitor to such a mammal are provided.
    Type: Grant
    Filed: February 26, 2016
    Date of Patent: January 1, 2019
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Haidong Dong, Eugene D. Kwon, Svetomir N. Markovic, Christopher J. Krco
  • Patent number: 10160811
    Abstract: The present invention concerns dosages for treatment of human cancer patients with an anti-Epidermal Growth Factor Receptor (EGFR) antibody.
    Type: Grant
    Filed: November 6, 2013
    Date of Patent: December 25, 2018
    Assignee: Genentech, Inc.
    Inventors: Sharon A. Baughman, Steven Shak
  • Patent number: 10155800
    Abstract: The present application relates to CTLA4-Ig immunoadhesins that target CD80 and CD86, and their use, particularly for therapeutic purposes.
    Type: Grant
    Filed: May 19, 2016
    Date of Patent: December 18, 2018
    Assignee: Xencor, Inc.
    Inventors: Gregory A. Lazar, Matthew J. Bernett
  • Patent number: 10155037
    Abstract: The present invention provides antagonizing antibodies that bind to programmed cell death protein 1 (PD-1) and methods of using same. The anti-PD-1 antibodies can be used therapeutically alone or in combination with other therapeutics to treat cancer and other diseases.
    Type: Grant
    Filed: December 3, 2015
    Date of Patent: December 18, 2018
    Assignee: Rinat Neuroscience Corp.
    Inventors: Yasmina Noubia Abdiche, Weihsien Ho, Arvind Rajpal, Sawsan Youssef
  • Patent number: 10150813
    Abstract: The disclosure provides anti-B7-H4 antibodies and immunoconjugates and methods of using the same.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: December 11, 2018
    Assignee: Genentech, Inc.
    Inventors: Steven R. Leong, Andrew Polson, Paul Polakis, Yan Wu, Wei-Ching Liang, Ron Firestein
  • Patent number: 10144778
    Abstract: A pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS that does not include the autoimmune neuroinflammatory disease, relapsing-remitting multiple sclerosis (RRMS), is provided. The pharmaceutical composition is for administration by a dosage regimen comprising at least two courses of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session.
    Type: Grant
    Filed: March 12, 2015
    Date of Patent: December 4, 2018
    Assignee: Yeda Research and Development Co. Ltd
    Inventors: Michal Eisenbach-Schwartz, Kuti Baruch, Neta Rosenzweig
  • Patent number: 10144779
    Abstract: The instant disclosure provides antibodies that specifically bind to human CTLA-4 and antagonize CTLA-4 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.
    Type: Grant
    Filed: May 27, 2016
    Date of Patent: December 4, 2018
    Assignees: AGENUS INC., LUDWIG INSTITUTE FOR CANCER RESEARCH LTD, MEMORIAL SLOAN KETTERING CANCER CENTER
    Inventors: Marc van Dijk, Cornelia Anne Mundt, Gerd Ritter, David Schaer, Jedd David Wolchok, Taha Merghoub, David Adam Savitsky, Nicholas Stuart Wilson